Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

Exclusion Criteria

• •Patients will be excluded if they meet ANY of the following criteria:
• •Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
• •Have previously completed or withdrawn from this study or any other study investigating pemetrexed
• •Pregnancy or breast-feeding
• •Serious concomitant systemic disorders (i.e. active infection) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study
• •Second active primary malignancy (except in situ carcinoma of the cervix, adequately treated non-melanomatous carcinoma of the skin, low grade (Gleason score less than or equal to 6), localized adenocarcinoma of the prostate or other malignancy treated at least 2 years previously with no evidence of recurrence